Genetic/epigenetic changes far outweigh somatic gene mutations in almost all human cancer types. They are important factors affecting gene expression and cellular phenotype in addition to DNA sequences. Research mainly focuses on DNA methylation, histone modification, non-coding RNA regulation, chromatin structure remodelling and transcriptomics. The combination of different types of genetic/epigenetic drugs with chemoimmunotherapy agents has been put to a wide range of anti-tumour therapeutic applications, while the combination of genetic/epigenetic therapy and immunotherapy has also gained data support and hopes to discover enzymes involved in chromatin remodelling to produce novel genetic/epigenetic modulators. At the same time, it is also hoped that with the in-depth study of genetic/epigenetic molecular mechanisms, the understanding of the etiology and pathogenesis of various cancer types is no longer limited to changes at the genetic level, and the exploration of genetic/epigenetic drugs can bring bright prospects for cancer treatment.

In addition, nanomaterials cause alterations in genetic/epigenetic effects. Relevant studies mainly include DNA methylation, hydroxymethylation changes of histone modifications and miRNA expression. Whether genetic/epigenetic effects mediated by nanomaterials are heritable remains to be investigated.

This Research Topic aims at reporting the latest progress on genetic/epigenetic studies and omics studies for oral and esophageal squamous cell carcinoma. We hope to find novel methods to treat these carcinomas though lab research and building animal models.

We welcome submissions of Original Research, Review, Mini Review on the recent advances in the areas below:

• Genetic/epigenetic regulators
• Nano-materials and their modulation on genetic/epigenetic effects;
• Development of preclinical models for human genetic/epigenetic genomics;
• Multi-omics combined to explore the molecular mechanism of tumours and screen pathogenic targets, such as methylation, histone modification, etc;
• Genetic/epigenetic exploration that may translate into biomarkers or treatment regimens for clinical efficacy monitoring and prognostic assessment.

Note: Submissions consisting solely of bioinformatic investigation of publicly available genomic / transcriptomic data without experimental or in situ validation to support conclusions are not in scope for this Research Topic.

Submit your idea

Impact

Frontiers in Oncology

Participating Journals

Impact